NeuroVision Imaging Inc. has received an additional investment from the Alzheimer's Drug Discovery Foundation to hasten development of a novel blood-based lab test to provide detection and measurement of biomarkers for Alzheimer's disease and other dementias before clinical onset.
NeuroVision is a California-based biotechnology company that develops and commercializes retinal and fluid biomarkers for the treatment of retinal diseases.